Johnson & Johnson to Fight $1.2 Billion Fine

April 12, 2012
Said its antipsychotic drug Risperdal complied with all laws and regulations

Johnson & Johnson ( IW 1000/54) on April 11 that it would fight an Arkansas judge's order to pay a $1.2 billion fine for deceptively marketing its antipsychotic drug Risperdal.

Janssen Pharmaceuticals, a J&J subsidiary, said it was ordered to pay the fine, despite having provided evidence during a trial that the company had complied with all laws and regulations.

"We are disappointed with the judge's decision on penalties. If our motion for a new trial is denied, we will appeal," said Teresa Mueller, a Janssen spokeswoman.

Janssen noted that Arkansas Medicaid, the state's health care program for the poor, spent $8.1 million on prescriptions for the drug, generically known as risperidone, which treats schizophrenia and bipolar mania, during the period being examined.

"The state did not show any Arkansas patient was ever harmed by using Risperdal, that any Arkansas physician or Arkansas Medicaid was ever misled by the drug's label or package insert, or that the state ever paid for a Risperdal prescription that was not properly written and eligible for reimbursement," Mueller said.

Copyright Agence France-Presse, 2012

About the Author

Agence France-Presse

Copyright Agence France-Presse, 2002-2024. AFP text, photos, graphics and logos shall not be reproduced, published, broadcast, rewritten for broadcast or publication or redistributed directly or indirectly in any medium. AFP shall not be held liable for any delays, inaccuracies, errors or omissions in any AFP content, or for any actions taken in consequence.

Sponsored Recommendations

Voice your opinion!

To join the conversation, and become an exclusive member of IndustryWeek, create an account today!